Abcam Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Abcam Plc (ABCM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Abcam Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 447M vs 275M combined for its competitors (62.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+29.3%) for its tracked peer group.
- Profitability: Its -2.4% net margin compares with -14.8% for the peer group.
- Peer revenue share: Abcam Plc accounted for 83.4% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ABCM Sales vs. its Competitors, Q4 2022
With a net margin of -2.35 %, Abcam Plc achieved higher profitability than its competitors (-14.76 %).
Abcam Plc generated 83.44 % of the combined sales of its peer group.
API endpoints for this dataset
Abcam Plc vs. its Competitors, Q4 2022
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Abcam Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Abcam Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Abcam Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (28) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Abcam Plc's competitor groups requires a Commercial License.
Abcam Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Abcam Plc | No | Yes | No | Yes |
| Competitors combined (3) | ||||
| High-Confidence Competitors (28) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 62.50 % (5 of 8) | 25.00 % (2 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ABCM Stock Performance relative to its Competitors
ABCM Stock Performance relative to High-Confidence Competitors
ABCM Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cryoport inc | 282.9% | Outperformed |
| 2 | Immunoprecise Antibodies Ltd | 282.9% | Outperformed |
| 3 | Harvard Bioscience Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Abcam Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Abcam Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Abcam Plc |
5,548.89 | 447.47 |
 Cryoport inc |
963.46 | 186.45 |
 Immunoprecise Antibodies Ltd |
69.11 | 17.60 |
 Harvard Bioscience Inc |
37.84 | 88.16 |
| SUBTOTAL | 6,619.29 | 739.68 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Abcam Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Abcam Plc's Competitors Named by the Company
Competitive relationships identified from Abcam Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Agilent Technologies inc | Company report | 85% |
| Volitionrx Limited | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
| Nephros Inc | Company report | 85% |
| Accelerate Diagnostics Inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Co diagnostics Inc | Company report | 85% |
| Manhattan Scientifics Inc | Company report | 85% |
| Xylem Inc | Company report | 85% |
| T2 Biosystems Inc | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| Bluejay Diagnostics Inc | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Envista Holdings Corporation | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Quanterix Corporation | Company report | 85% |
| Cytek Biosciences Inc | Company report | 85% |
| 908 Devices inc | Company report | 85% |
| Northview Acquisition Corp | Company report | 85% |
| Quantum si Incorporated | Company report | 85% |
| Mdxhealth Sa | Company report | 85% |
| Idex Corp | Company report | 85% |
| Entegris Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| OPGN | Company report | 85% |
| Capforce Inc | Company report | 85% |
| Dover Corp | Company report | 85% |
| Esco Technologies inc | Company report | 85% |
| Parker hannifin Corporation | Company report | 85% |
| Harvard Bioscience Inc | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Veralto Corporation | Company report | 85% |
| Line Corp | Company report | 85% |
| Cue Health Inc | Company report | 85% |
| Illinois Tool Works Inc | Company report | 85% |
| Steris Plc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Dentsply Sirona Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Rockwell Automation Inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Roper Technologies Inc | Company report | 85% |
| Intuitive Surgical Inc | Company report | 85% |
| Emerson Electric Co | Company report | 85% |
| Steris Plc | Company report | 85% |
| Medtronic Plc | Company report | 85% |
| West Pharmaceutical Services Inc | Company report | 85% |
| Mativ Holdings Inc | Company report | 85% |
| Varian Medical Systems Inc | Company report | 85% |
| Cardinal Health Inc | Company report | 85% |
| Point Of Care Nano technology Inc | Company report | 85% |
| Abb Ltd | Company report | 85% |
| Bruker Corporation | Company report | 85% |
| Orasure Technologies Inc | Company report | 85% |
| Becton Dickinson And Company | Company report | 85% |
| Rapid Micro Biosystems Inc | Company report | 85% |
| Honeywell International Inc | Company report | 85% |
| Itron Inc | Company report | 85% |
| Milestone Scientific Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Repligen Corp | Company report | 85% |
| Guided Therapeutics Inc | Company report | 85% |
| Badger Meter Inc | Company report | 85% |
| 3m Company | Company report | 85% |
| Itt Inc | Company report | 85% |
| Vishay Precision Group Inc | Company report | 85% |
| Avantor Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Abcam Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Abcam Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Cryoport inc | Life Sciences Services 58.40 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Abcam Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Abcam Plc | 5,549 | - | - |
| Cryoport inc | 963 | 252,645 | -58,789 |
| Immunoprecise Antibodies Ltd | 69 | 13,773 | -16,982 |
| Harvard Bioscience Inc | 38 | 260,071 | -30,714 |
| PEERS TOTAL | 1,070 | 124,084 | -32,060 |
Abcam Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cryoport inc | Americas 73.14 % |
| Harvard Bioscience Inc | US 43.49 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Abcam Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 60.45 % | 34.84 % (avg) | +25.6 pp |
| Operating Margin | -2.79 % | industry median | +121.5 pp |
| EBITDA Margin | 7.13 % | -2.62 % (avg) | +9.8 pp |
| Capital Intensity (Capex / Revenue) | 4.64 % | 8.89 % (avg) | -4.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Abcam Plc's Strategic Group Map
Abcam Plc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Abcam Plc's trailing-12-month revenue growth of 3.1% and operating margin of -2.8% compares with an average of 4.6% growth and -0.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Abcam Plc sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Abcam Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.64 % vs industry average 8.89 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Abcam Plc's dedicated Suppliers and Customers pages, not here.
Abcam Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Abcam Plc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Abcam Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 121.5 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 19.9 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Abcam Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Abcam Plc | 0.44 | 1.27 | - |
| Cryoport inc | 2.02 | 2.73 | 0.28 |
| Immunoprecise Antibodies Ltd | 1.20 | 2.08 | - |
| Harvard Bioscience Inc | 0.23 | 1.49 | 3.15 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Abcam Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Abcam Plc | Q4 2022 | +3.1 % | - |
| Cryoport inc | Q2 2026 | +7.7 % | - |
| Immunoprecise Antibodies Ltd | Q1 2025 | -3.1 % | - |
| Harvard Bioscience Inc | Q2 2026 | +16.4 % | - |
| PEERS TOTAL | +3.8 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Abcam Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Abcam Plc | Q4 2022 | -9.7 % | -56.2 % |
| Cryoport inc | Q2 2026 | +8.6 % | +58.2 % |
| Immunoprecise Antibodies Ltd | Q1 2025 | -14.7 % | -44.6 % |
| Harvard Bioscience Inc | Q2 2026 | +26.2 % | +293.1 % |
Abcam Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Abcam Plc | - | - | - |
| Cryoport inc | - | - | - |
| Immunoprecise Antibodies Ltd | - | - | - |
| Harvard Bioscience Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Abcam Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Abcam Plc | - | 12.40 |
| Cryoport inc | - | 5.17 |
| Immunoprecise Antibodies Ltd | - | 3.93 |
| Harvard Bioscience Inc | - | 0.43 |
| PEERS AVERAGE | - | 8.95 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.